According to the official website of the Wuhan Institute of Virology, Chinese Academy of Sciences, recently, the Wuhan Institute of Virology / Big Science Research Center for Biosafety, Chinese Academy of Sciences, and the National Institute for Emergency Control and Prevention of Drug Engineering Technology Research Institute of the Academy of Military Medical Sciences of the Chinese Academy of Sciences have jointly conducted research on the suppression of 2019 new types of coronavirus 2019-nCoV) made significant progress in drug screening.
Related research results were published under the title of “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”. In Cell Research, a well-known international academic journal with independent intellectual property rights in China.
The study demonstrated that on Vero E6 cells, the half effective concentration of Remdesivir (GS-5734) for 2019-nCoV EC50 = 0.77 uM (micromoles per litre), the selection index SI is greater than 129; Chloroquine phosphate EC50 = 1.13 uM, SI is greater than 88, indicating that the two drugs mentioned above can effectively inhibit 2019-nCoV infection at the cellular level, and their role in the human body has yet to be clinically verified.
It is understood that Remdesivir (GS-5734) is a nucleoside analogue. Phase II and III clinical studies on Ebola hemorrhagic fever are currently being conducted in the DRC.
Chloroquine phosphate has been used in the treatment of malaria since the 1940s and later in rheumatoid arthritis.
The preliminary results of the above two drugs at the cellular level to effectively inhibit 2019 new coronavirus infection have previously been reported to the national, provincial and municipal relevant departments in various forms.
In order to serve the prevention and control of the epidemic, the partners of the two partners have jointly stated that among the above-mentioned drugs with anti-coronavirus effect in 2019, we do not apply for related patents for chloroquine phosphate, which has been marketed in China and can fully realize independent supply. The enthusiasm of enterprises to participate in epidemic prevention and control;
Regarding the drug Radexivir that has not been marketed in China and has intellectual property barriers, we applied for a Chinese invention patent on January 21 (from the purpose of anti-coronavirus 2019) from the perspective of protecting national interests And will enter major countries around the world through the PCT (Patent Cooperation Agreement) approach.
If relevant foreign companies intend to contribute to the prevention and control of China’s epidemic, we both agree that if the state needs it, we will not require the implementation of the rights claimed by the patent for the time being, and we hope to work with foreign pharmaceutical companies to minimize the impact of epidemic prevention and control.